SEMINAR ON
RATE- CONTROLLED DRUG
DELIVERY BY USING RATE-
PREPROGRAMMED DRUG
DELIVERY SYSTEMS



PRESENTED BY:
GANDHI SONAM MUKESHCHANDRA
INTRODUCTION

 Conventional drug delivery systems (DDS)




                                             2
Sustained release and controlled release DDS



        70


        60


        50


        40
                                               Solution
                                               Dexatrim
        30
                                               Acutrim

        20


        10


         0
             0   5   10    15   20   25   30




                                                          3
CLASSIFICATION


 Rate- preprogrammed drug delivery systems


 Activation – modulated drug delivery systems


 Feedback- regulated drug delivery systems


 Site- targeting drug delivery systems




                                                 4
RATE- PREPROGRAMMED DDS


 Release of drug molecules from the delivery systems has been
   preprogrammed at specific rate profiles


 Diffusion of drug molecules into the medium is controlled


CLASSIFICATION OF RATE- PREPROGRAMMED DDS


A. Polymer membrane permeation-controlled drug delivery systems


B. Polymer matrix diffusion-controlled drug delivery systems


C. Micro reservoir partition-controlled drug delivery systems

                                                                  5
A. POLYMER MEMBRANE PERMEATION-CONTROLLED
   DDS


 Drug release surface of the reservoir compartment is rate-
   controlling polymeric membrane.


 Polymeric membrane can be nonporous, microporous or
   semi permeable in nature.


 Encapsulation of drug in the reservoir is accomplished by
   injection molding, spray coating, capsulation or
   microencapsulation.


 Q/t = [(Km/r Ka/m Dd Dm)/( Km/r Dm hd + Ka/m Dd hm)] cR

                                                               6
 Release of drug is controlled by controlling the partition
   coefficient and diffusivity of the drug molecule and the
   thickness of the rate-controlling membrane


EXAMPLES
PROGESTASERT IUD:
 reservoir - suspension of progesterone crystals in silicone
   medical fluid


 Membrane- nonporous membrane of ethylene vinyl acetate
   copolymer


 Deliver natural progesterone continuously in the uterine cavity
   at a daily dosage rate of at least 65 µg/day to achieve
   contraception for1 year.
                                                                    7
PROGESTASERT




               8
OCUSERT SYSTEM
 thin disk of pilocarpine alginate complex sandwiched
  between two transparent sheets of microporous ethylene-
  vinyl acetate copolymer membrane.




                                                            9
 Either 20 or 40 µg/hr of pilocarpine is released


TRANSDERM-NITRO
 Nitroglycerin-lactose triturate in the silicone medical fluid
 Micro porous membrane of ethylene-vinyl acetate
   copolymer
 Thin layer of pressure-sensitive silicone adhesive polymer is
   coated




                                                                  10
B. POLYMER MATRIX DIFFUSION-CONTROLLED DDS
 Reservoir is prepared by homogenously dispersing drug particles in
  a rate-controlling polymer matrix.




                                                                       11
 Q/t1/2 = (2ACRDp)1/2


 release of drug is controlled by controlling the loading
   dose, polymer solubility of the drug, and its diffusivity in the
   polymer matrix

EXAMPLES


NITRO-DUR
 Nitro-glycerine transdermal patch


 for 24 hr to provide a continuous transdermal infusion of
   nitro-glycerine at a dosage rate of 0.5 mg/cm2/day for the
   treatment of angina pectoris.

                                                                      12
NITRO-DUR




            13
C. MICRORESERVOIR PARTITION- CONTROLLED DRUG DELIVERY
   SYSTEMS
 Micro dispersion of an aqueous suspension of drug using a high-
  energy dispersion technique in a bio-compatible polymer,(Eg.
  silicone elastomers), forms a homogenous dispersion of many
  discrete, unleachable, microscopic drug reservoirs.
 device can be further coated with a layer of biocompatible polymer
  to modify the mechanism and the rate of drug release




                                                                       14
 Release of drug molecules from this type of CRDDS can
  follow either dissolution or a matrix diffusion-controlled
  process depending upon the relative magnitude of Sl and Sp


EXAMPLES
NITRODISC SYSTEM
 Nitro-glycerine in silicone elastomer
 0.5mg/cm2 for once-a-day




                                                               15
ACTIVATION MODULATED DDS
 Drug delivery is activated and controlled by physical, chemical or bio-
     chemical processes or facilitated by the energy supplied externally



Classification of activation modulated DDS

 Based on the nature of the process applied or the type of energy used



1.   Physical means

2.   Chemical means

3.   Biological means



                                                                      16
DDS activated by physical means


a. Osmotic pressure- activated DDS

b. Hydrodynamic pressure activated DDS

c.   Vapour pressure activated DDS

d. Mechanically activated DDS

e. Magnetically activated DDS

f.   Sonophorosis activated DDS

g. Iontophoresis activated DDS

h. Hydration activated DDS


                                         17
1. Osmotic pressure- activated DDS


   drug reservoir can be a solution contained within an impermeable
    collapsable tube.

   This is covered with osmotic agent place in a rigid semi permeable
    housing with controlled water permeability.

   The rate of drug release is modulated by the gradient of osmotic
    pressure.


                          Q/t = PwAm (πs-πe) /hm

Pw = water permeability
Am = effective surface area
hm =thickness of the semi permeable housing                 18
Vasopressin

              19
2. Hydrodynamic pressure activated DDS

 hydrodynamic pressure is used as the source of energy to activate
  the drug release.




                                                           20
Q/t = Pf Am/hm (θs – θe)


Pf = fluid permeability



Am = effective surface area



hm = thickness of the wall with annular openings



θs – θe = difference in hydrodynamic pressure between the
   DDS and the environment

                                                            21
3. Vapour pressure- activated drug delivery systems



 Drug inside infusion compartment is separated from pumping
  compartment by freely movable partition.

 Pumping compartment contains a fluorocarbon fluid that
  vaporizes at body temperature

 The    vapour    pressure   created    moves    the   partition
  upward, forcing the drug to be delivered.

 Eg: INFUSAID implants (heparin)



                                                         22
1. Flow regulator, 2. silicone polymer coating, 3. patrition,
4. Pumping compartment, 5. Infusate compartment, 6. fluorocarbon
fluid filling tube, 7. filter assembly, 8. inlet septum for percutaneous
refill of infusate, 9. needle stop.
                                                                 23
Q/t= d4(Ps-P-e)/40.74µl


d    & l = the inner diameter and the length of the delivery
    cannula, respectively



Ps-P-e = difference between the vapour pressure in the
    pumping compartment and the site of implantation.



µ = viscosity of the drug formulation used.
                                                         24
4. Mechanically activated drug delivery system

 Equipped with a mechanically activated pumping system

 A measured dose of drug formulation is reproducibly delivered

 The volume of solution delivered is controllable, as small as 10-
  100µl

 Volume of solution delivered is independent of the force &
  duration of activation applied as well as the solution volume in the
  container.

 Example is the development of metered dose nebulizer for the
  intranasal administration of a precision dose of buserelin (LHRH).


                                                             25
26
5. Magnetically activated drug delivery systems
 Drug reservoir is a dispersion of peptide or protein powders in a
  polymer matrix
 Low    rate of delivery is improved by incorporating
  electromagnetically triggered vibration mechanism




                                                          27
 Coating polymer can be a ethylene-vinyl acetate copolymer or
   silicon elastomers.

 These systems have been used to deliver protein drugs, such as
   bovine serum albumin

6. Sonophoresis-activated drug delivery systems

 Utilize ultrasonic energy to activate the delivery of the drugs from
   a polymeric drug delivery device

 can be fabricated from either a non degradable polymer, such as
   ethylene-vinyl acetate copolymer,

   a bio erodible polymer such as poly[bis(p-carboxyphenoxy)alkane
   anhydride].

                                                              28
Sonophoresis-activated drug delivery systems




                                               29
7. Iontophoresis-activated drug delivery systems


 uses electrical current to activate and to modulate the
  diffusion of a charged drug molecule across the skin in a
  facilitated rate




                                                        30
 skin permeation rate of a charged molecule i consist of 3 components

                       Jiisp = Jp+Je+Jc
   Jp = passive skin permeation flux
   Je = electrical current driven permeation flux
   Jc = convection flow-driven skin permeation flux

 IONSYS - fentanyl iontophoretic transdermal system




 Example : development of an iontophoretic DDS of dexamethasone
  sodium phosphate

                                                             31
8. Hydration-activated drug delivery system

 Depends on the hydration induced swelling process to activate the
   release of drug

 Drug reservoir is homogeneously dispersed in a swellable polymer
   matrix fabricated from a hydrophilic polymer

 Release of the drug is controlled by the rate of swelling of the polymer
   matrix.

 Example is VALRELEASE tablet- diazepam in hydrocolloid and
   pharmaceutical excipients.

 In stomach absorbs the gastric fluid & forms colloidal gel that starts
   from the tablet surface and grows inward.
                                                               32
 release of the drug is controlled by matrix diffusion through this
  gel barrier




                                                            33
REFERENCES



 NOVEL DRUG DELIVERY SYSTEMS, 2nd edition,Yie W. Chien

 CONTROLLED            DRUG   DELIVERY-    FUNDAMENTALS       AND
    APPLICATIONS, 2nd edition,    edited by Joseph R. Robinson and
    Vincent H. L. Lee

   http://www.rxlist.com/ionsys-drug.htm




                                                          34
THANK YOU




            35

Rate controlled drug delivery by using rate preprogrammed drug delivery systems

  • 1.
    SEMINAR ON RATE- CONTROLLEDDRUG DELIVERY BY USING RATE- PREPROGRAMMED DRUG DELIVERY SYSTEMS PRESENTED BY: GANDHI SONAM MUKESHCHANDRA
  • 2.
    INTRODUCTION  Conventional drugdelivery systems (DDS) 2
  • 3.
    Sustained release andcontrolled release DDS 70 60 50 40 Solution Dexatrim 30 Acutrim 20 10 0 0 5 10 15 20 25 30 3
  • 4.
    CLASSIFICATION  Rate- preprogrammeddrug delivery systems  Activation – modulated drug delivery systems  Feedback- regulated drug delivery systems  Site- targeting drug delivery systems 4
  • 5.
    RATE- PREPROGRAMMED DDS Release of drug molecules from the delivery systems has been preprogrammed at specific rate profiles  Diffusion of drug molecules into the medium is controlled CLASSIFICATION OF RATE- PREPROGRAMMED DDS A. Polymer membrane permeation-controlled drug delivery systems B. Polymer matrix diffusion-controlled drug delivery systems C. Micro reservoir partition-controlled drug delivery systems 5
  • 6.
    A. POLYMER MEMBRANEPERMEATION-CONTROLLED DDS  Drug release surface of the reservoir compartment is rate- controlling polymeric membrane.  Polymeric membrane can be nonporous, microporous or semi permeable in nature.  Encapsulation of drug in the reservoir is accomplished by injection molding, spray coating, capsulation or microencapsulation.  Q/t = [(Km/r Ka/m Dd Dm)/( Km/r Dm hd + Ka/m Dd hm)] cR 6
  • 7.
     Release ofdrug is controlled by controlling the partition coefficient and diffusivity of the drug molecule and the thickness of the rate-controlling membrane EXAMPLES PROGESTASERT IUD:  reservoir - suspension of progesterone crystals in silicone medical fluid  Membrane- nonporous membrane of ethylene vinyl acetate copolymer  Deliver natural progesterone continuously in the uterine cavity at a daily dosage rate of at least 65 µg/day to achieve contraception for1 year. 7
  • 8.
  • 9.
    OCUSERT SYSTEM  thindisk of pilocarpine alginate complex sandwiched between two transparent sheets of microporous ethylene- vinyl acetate copolymer membrane. 9
  • 10.
     Either 20or 40 µg/hr of pilocarpine is released TRANSDERM-NITRO  Nitroglycerin-lactose triturate in the silicone medical fluid  Micro porous membrane of ethylene-vinyl acetate copolymer  Thin layer of pressure-sensitive silicone adhesive polymer is coated 10
  • 11.
    B. POLYMER MATRIXDIFFUSION-CONTROLLED DDS  Reservoir is prepared by homogenously dispersing drug particles in a rate-controlling polymer matrix. 11
  • 12.
     Q/t1/2 =(2ACRDp)1/2  release of drug is controlled by controlling the loading dose, polymer solubility of the drug, and its diffusivity in the polymer matrix EXAMPLES NITRO-DUR  Nitro-glycerine transdermal patch  for 24 hr to provide a continuous transdermal infusion of nitro-glycerine at a dosage rate of 0.5 mg/cm2/day for the treatment of angina pectoris. 12
  • 13.
  • 14.
    C. MICRORESERVOIR PARTITION-CONTROLLED DRUG DELIVERY SYSTEMS  Micro dispersion of an aqueous suspension of drug using a high- energy dispersion technique in a bio-compatible polymer,(Eg. silicone elastomers), forms a homogenous dispersion of many discrete, unleachable, microscopic drug reservoirs.  device can be further coated with a layer of biocompatible polymer to modify the mechanism and the rate of drug release 14
  • 15.
     Release ofdrug molecules from this type of CRDDS can follow either dissolution or a matrix diffusion-controlled process depending upon the relative magnitude of Sl and Sp EXAMPLES NITRODISC SYSTEM  Nitro-glycerine in silicone elastomer  0.5mg/cm2 for once-a-day 15
  • 16.
    ACTIVATION MODULATED DDS Drug delivery is activated and controlled by physical, chemical or bio- chemical processes or facilitated by the energy supplied externally Classification of activation modulated DDS  Based on the nature of the process applied or the type of energy used 1. Physical means 2. Chemical means 3. Biological means 16
  • 17.
    DDS activated byphysical means a. Osmotic pressure- activated DDS b. Hydrodynamic pressure activated DDS c. Vapour pressure activated DDS d. Mechanically activated DDS e. Magnetically activated DDS f. Sonophorosis activated DDS g. Iontophoresis activated DDS h. Hydration activated DDS 17
  • 18.
    1. Osmotic pressure-activated DDS  drug reservoir can be a solution contained within an impermeable collapsable tube.  This is covered with osmotic agent place in a rigid semi permeable housing with controlled water permeability.  The rate of drug release is modulated by the gradient of osmotic pressure. Q/t = PwAm (πs-πe) /hm Pw = water permeability Am = effective surface area hm =thickness of the semi permeable housing 18
  • 19.
  • 20.
    2. Hydrodynamic pressureactivated DDS  hydrodynamic pressure is used as the source of energy to activate the drug release. 20
  • 21.
    Q/t = PfAm/hm (θs – θe) Pf = fluid permeability Am = effective surface area hm = thickness of the wall with annular openings θs – θe = difference in hydrodynamic pressure between the DDS and the environment 21
  • 22.
    3. Vapour pressure-activated drug delivery systems  Drug inside infusion compartment is separated from pumping compartment by freely movable partition.  Pumping compartment contains a fluorocarbon fluid that vaporizes at body temperature  The vapour pressure created moves the partition upward, forcing the drug to be delivered.  Eg: INFUSAID implants (heparin) 22
  • 23.
    1. Flow regulator,2. silicone polymer coating, 3. patrition, 4. Pumping compartment, 5. Infusate compartment, 6. fluorocarbon fluid filling tube, 7. filter assembly, 8. inlet septum for percutaneous refill of infusate, 9. needle stop. 23
  • 24.
    Q/t= d4(Ps-P-e)/40.74µl d & l = the inner diameter and the length of the delivery cannula, respectively Ps-P-e = difference between the vapour pressure in the pumping compartment and the site of implantation. µ = viscosity of the drug formulation used. 24
  • 25.
    4. Mechanically activateddrug delivery system  Equipped with a mechanically activated pumping system  A measured dose of drug formulation is reproducibly delivered  The volume of solution delivered is controllable, as small as 10- 100µl  Volume of solution delivered is independent of the force & duration of activation applied as well as the solution volume in the container.  Example is the development of metered dose nebulizer for the intranasal administration of a precision dose of buserelin (LHRH). 25
  • 26.
  • 27.
    5. Magnetically activateddrug delivery systems  Drug reservoir is a dispersion of peptide or protein powders in a polymer matrix  Low rate of delivery is improved by incorporating electromagnetically triggered vibration mechanism 27
  • 28.
     Coating polymercan be a ethylene-vinyl acetate copolymer or silicon elastomers.  These systems have been used to deliver protein drugs, such as bovine serum albumin 6. Sonophoresis-activated drug delivery systems  Utilize ultrasonic energy to activate the delivery of the drugs from a polymeric drug delivery device  can be fabricated from either a non degradable polymer, such as ethylene-vinyl acetate copolymer, a bio erodible polymer such as poly[bis(p-carboxyphenoxy)alkane anhydride]. 28
  • 29.
  • 30.
    7. Iontophoresis-activated drugdelivery systems  uses electrical current to activate and to modulate the diffusion of a charged drug molecule across the skin in a facilitated rate 30
  • 31.
     skin permeationrate of a charged molecule i consist of 3 components Jiisp = Jp+Je+Jc Jp = passive skin permeation flux Je = electrical current driven permeation flux Jc = convection flow-driven skin permeation flux  IONSYS - fentanyl iontophoretic transdermal system  Example : development of an iontophoretic DDS of dexamethasone sodium phosphate 31
  • 32.
    8. Hydration-activated drugdelivery system  Depends on the hydration induced swelling process to activate the release of drug  Drug reservoir is homogeneously dispersed in a swellable polymer matrix fabricated from a hydrophilic polymer  Release of the drug is controlled by the rate of swelling of the polymer matrix.  Example is VALRELEASE tablet- diazepam in hydrocolloid and pharmaceutical excipients.  In stomach absorbs the gastric fluid & forms colloidal gel that starts from the tablet surface and grows inward. 32
  • 33.
     release ofthe drug is controlled by matrix diffusion through this gel barrier 33
  • 34.
    REFERENCES  NOVEL DRUGDELIVERY SYSTEMS, 2nd edition,Yie W. Chien  CONTROLLED DRUG DELIVERY- FUNDAMENTALS AND APPLICATIONS, 2nd edition, edited by Joseph R. Robinson and Vincent H. L. Lee  http://www.rxlist.com/ionsys-drug.htm 34
  • 35.